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Human immunodeﬁciency virus type 1 (HIV-1) resistance to CCR5 antagonists, including maraviroc
(MVC), results from alterations in the HIV-1 envelope glycoproteins (Env) enabling recognition of
antagonist-bound CCR5. Here, we characterized tropism alterations for CD4+ T-cell subsets and
macrophages by Envs from two subjects who developed MVC resistance in vivo, which displayed either
relatively efﬁcient or inefﬁcient recognition of MVC-bound CCR5. We show that MVC-resistant Env with
efﬁcient recognition of drug-bound CCR5 displays a tropism shift for CD4+ T-cell subsets associated with
increased infection of central memory T-cells and reduced infection of effector memory and transitional
memory T-cells, and no change in macrophage infectivity. In contrast, MVC-resistant Env with inefﬁcient
recognition of drug-bound CCR5 displays no change in tropism for CD4+ T-cell subsets, but exhibits a
signiﬁcant reduction in macrophage infectivity. The pattern of HIV-1 tropism alterations for susceptible
cells may therefore be variable in subjects with MVC resistance.
& 2013 Elsevier Inc. All rights reserved.Introduction
The entry of human immunodeﬁciency virus type 1 (HIV-1) into
cells is initiated by the interaction between the gp120 glycoproteins of
the HIV-1 envelope (Env) with cellular CD4 and a coreceptor, either
CCR5 or CXCR4 [reviewed in (Gorry and Ancuta, 2011)]. Maraviroc
(MVC) inhibits HIV-1 entry by binding to a hydrophobic pocket in the
transmembrane helices of CCR5, which alters the conformation of thell rights reserved.
net Institute, 85 Commercial
mroche@burnet.edu.
e, WA, USA.CCR5 extracellular loops (ECLs) rendering them unrecognizable by
gp120 (Gorry et al., 2010; Tilton and Doms, 2010). Maraviroc, similar to
other CCR5 antagonists such as vicriviroc (VVC) and aplaviroc (APL)
(Dragic et al., 2000; Maeda et al., 2008; Seibert et al., 2006), is
therefore an allosteric inhibitor of HIV-1 entry.
Maraviroc is currently being used as an HIV-1 antiretroviral
therapy for both treatment-experienced and antiretroviral therapy
(ART)-naïve adults who have no evidence of CXCR4 using virus in
their plasma (Gorry et al., 2010). However, similar to other classes
of HIV-1 antiretrovirals, drug resistance to CCR5 antagonists can
occur. Treatment failure can result from the emergence of CXCR4-
using HIV-1 strains that were present at undetectable levels prior
to MVC therapy, and also from the development of bona ﬁde
resistance (Westby et al., 2006), where adaptive mutations in
gp120 enable recognition of- and entry via the drug bound
Table 1
Viral loads and CD4+ T-cell counts of the study subjects.
Subject 17 Subject 24
Days
post
MVC
Viral load (HIV-1
RNA copies/ml)
CD4 count
(cells/μl)
Days
post
MVC
Viral load (HIV-1
RNA copies/ml)
CD4
count
(cells/μl)
−6 75800 N/A −6 179000 N/A
1 45500 177 1 214000 4
15 68600 189 15 1860 8
29 45400 167 29 158 19
57 653 262 44 497 16
85 82 289 86 14400 10
117 4590 312 114 44100 59
140 2660 333 144 66100 56
169 12600 224 172 143000 26
Plasma viral loads were determined using Amplicor HIV-1 monitor v1.5 (Roche
Diagnostics). CD4 counts were determined by ﬂow cytometry. The resistant Envs
used in this study were derived from the day 169 sample for subject 17, and the day
172 sample for subject 24 (i.e., ∼24 weeks post commencement of MVC), and the
sensitive Envs were derived from the day-6 samples. NA, not available.
Table 2
Characteristics of MVC resistant Envs.
Envelope MPI a Δ in VERSA angle in
response to MVC b
Level of
resistance
Reference
17-Res 91.471.3% +37.41 Weak Roche et al.,
2013
MVC-Res 59.571.4% +12.11 Moderate Roche et al.,
2011a
24-Res 12.572.5% +8.61 Strong Roche et al.,
2013
The MPIs and VERSA vector angles have been reported previously for these Envs
(Roche et al., 2011b, 2013), and are summarized here to assist in the interpretation
of the CD4+ T-cell and macrophage tropism data.
a MPIs were determined using NP-2-CD4/CCR5 cells.
b The VERSA metrics shown represent the change in vector angle, when
comparing vector angles from experiments conducted in the presence of MVC
compared to those from experiments conducted without MVC. An increase in
change in the vector angle is inversely proportional to the level of MVC resistance
(Roche et al., 2011b).
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et al., 2010).
Resistance to MVC is characterized by plateaus in virus inhibition
curves which do not reach 100% inhibition, rather than by shifts in
IC50, indicating a non-competitive mechanism of resistance [discussed
in (Roche et al., 2011b; Westby et al., 2007)]. Results from phase III
clinical testing of MVC have shown that the maximal percentage
inhibition (MPI) of most MVC-resistant viruses range between 80–95%
when tested using the PhenoSense assay, although some resistant
viruses have MPIs as low as 20% (Mori et al., 2008). The MPI can be
used as a measure of how efﬁciently a resistant virus can recognize the
CCR5-antagonist bound conformation of CCR5; viruses with relatively
high MPIs (480%) are considered to have relatively inefﬁcient
recognition of drug-bound CCR5 compared to unbound CCR5, whereas
viruses with relatively low MPIs (o50%) are considered to have
relatively efﬁcient recognition of drug-bound CCR5 compared to
unbound CCR5.
Previous studies have shown that viruses sensitive to CCR5
antagonists rely on interactions with the N-terminus and the ECL2
region of CCR5, whereas resistant viruses frequently display an incre-
ased reliance on the N-terminal region (Berro et al., 2009; Henrich
et al., 2012; Ogert et al., 2009, 2010; Pfaff et al., 2010; Roche et al.,
2011b; Tilton et al., 2010). The signiﬁcance of altering the mechanism
of coreceptor engagement by CCR5 antagonist-resistant viruses on
HIV-1 pathogenesis is yet to be determined, but evidence suggests that
the tropism of HIV-1 for different susceptible cell types may be altered
as a result of resistance to CCR5 antagonists. For example, one study
examining resistance to APL showed that a viral variant with relatively
inefﬁcient usage of APL-bound CCR5 had altered CD4+ T-cell tropism,
characterized by relative sparing of central memory (CM) CD4+ T cells
(Pfaff et al., 2010). Another study of a MVC-resistant strain of HIV-1
that was generated in vitro showed a reduction in macrophage
infectivity due to inefﬁcient recognition of MVC-bound CCR5
expressed on the macrophage surface (Roche et al., 2011b). Implied
in both of these studies was that the continuation of CCR5 antagonist
therapy, even after the development of resistance, could maintain a
selection for variants that use CCR5 inefﬁciently for entry, thus
potentially sparing signiﬁcant cellular reservoirs from infection.
However, both of these studies characterized resistant viruses that
had relatively inefﬁcient recognition of antagonist-bound CCR5 (i.e.,
relatively high MPIs), and whether attenuated infectivity in CM T-cells
and macrophages is a common feature among CCR5 antagonist
resistant viruses that display differences in MPI is unknown.
In this study, we characterized the tropism alterations for CD4+
T-cell subsets and macrophages by Envs from two subjects who
developed MVC resistance in vivo, which displayed either relatively
efﬁcient or inefﬁcient recognition of MVC-bound CCR5, as shown by
MPIs of ∼10% and ∼90% in NP2-CD4/CCR5 cells, respectively. Our
results show that MVC-resistant Env with efﬁcient recognition of
drug-bound CCR5, which we consider is “strongly resistant”, displays a
tropism shift for CD4+ T-cell subsets associated with increased
infection of CM T-cells and reduced infection of effector memory
(EM) and transitional memory (TM) T-cells, and no change in macro-
phage infectivity. In contrast, MVC-resistant Env with inefﬁcient
recognition of drug-bound CCR5, which we consider is “weakly
resistant”, displays no change in tropism for CD4+ T-cell subsets, but
exhibits a signiﬁcant reduction in macrophage infectivity. Together,
our results show that the pattern of HIV-1 tropism alterations for
susceptible cells may be variable in subjects with MVC resistance.
Results and discussion
The panel of MVC resistant Envs has a spectrum of resistance levels
In this study, we characterized the tropism alterations for CD4+
T-cell subsets and macrophages associated with MVC resistance by3 distinct MVC resistant Env variants, as compared to matched MVC
sensitive parental Envs. The MVC resistant Envs comprise two clones
derived from two subjects (subjects 17 and 24) who developed MVC
resistance in vivo (Jubb et al., 2011; Mori et al., 2008; Pﬁzer Inc., 2007),
and whose phenotypes and genetic determinants of resistance have
been characterized recently (Roche et al., 2013). The plasma viral loads
and CD4+ T-cell counts of the study subjects from whom the Envs
were derived are shown in Table 1, and the salient features of the Envs
that are relevant for this study are summarized in Table 2. Brieﬂy, 17-
Res and 24-Res Envs exhibit divergent levels of MVC resistance, with
17-Res Env having an MPI of ∼90% in NP2-CD4/CCR5 cells, and 24-Res
Env having an MPI of ∼10%. The ability of these Envs to recognize the
MVC-bound conformation of CCR5 was also divergent, with 17-Res
Env displaying a greater change in VERSA (Viral Entry Receptor
Sensitivity Analysis) vector angles in response to MVC, as determined
by mathematical modeling of 293-Afﬁnoﬁle analyses (Chikere et al.,
2013; Johnston et al., 2009), as compared to those of 24-Res Env,
indicating that 17-Res Env is more CCR5-dependent than 24-Res Env
in the presence of MVC. Thus, 17-Res and 24-Res have relatively
inefﬁcient and efﬁcient abilities to recognize the MVC-bound con-
formation of CCR5, respectively, and are considered “weakly” resistant
and “strongly” resistant Envs, respectively. For comparison, we also
characterized the tropism alterations of MVC-Res Env (Roche et al.,
2011b), which was generated in vitro (Westby et al., 2007), as
compared to Env from its parental MVC sensitive virus (MVC-Sens).
Fig. 1. Strategy for identifying HIV-1 infected CD4+ T-cell subsets. A representative example of the strategy used to deﬁne CD4+ T-cell subsets. CD4+ T-cells infected with
Env-pseudotyped GFP reporter virus were ﬁrst gated on FSC Vs SSC and then viability (FSC Vs Viability dye). (A) HIV-1 infection was determined by CD3/GFP positivity and
used to govern the distribution of infection amongst CD4+ T-cell subsets. (B) CD3+CD4+GFP+ T-cells were gated on CD45RO expression (CD45RO Vs CD3) and divided into
CD45RO positive and negative cells. Each population, CD45RO positive and negative, was then plotted CCR7 Vs CD27 to deﬁne each T-cell subset. (C) CD45RO negative cells
were divided into naïve (CCR7+CD45RO-CD27+) and effector (EMRA; CCR7+CD45RO-CD27-) CD4+ T-cells. (D) CD45RO positive cells were divided into transitional memory
(TM; CCR7-CD45RO+CD27+), central memory (CM; CCR7+CD45RO+CD27+) and effector memory (EM; CCR7-CD45RO+CD27-) CD4+ T-cells. This gating strategy allowed EM
to be distinguished from TM, similar to methods used by Chomont et al. (2009), and the use of an additional cellular marker, CD27, also enabled better enumeration of T-cell
subsets, as described previously (Appay et al., 2008; De Rosa et al., 2001).
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level of MVC resistance, exhibiting an MPI of ∼60% in NP2-CD4/CCR5
cells and an intermediate change in VERSA vector angles for recogni-
tion of MVC-bound CCR5 (Roche et al., 2011b) (Table 2). Thus, the
availability of 3 well characterized MVC resistant Envs, which exhibit a
spectrum of levels of resistance and abilities to recognize MVC-bound
CCR5, offers a unique opportunity to better understand the inﬂuence
of differing resistance levels on cellular tropism alterations.
MVC resistant Envs have different patterns of altered T-cell tropism
To determine whether the different MVC resistant Envs have
different trends for CD4+ T-cell subset tropism, we ﬁrst performed
CD4+ T-cell infection assays with Env-pseudotyped GFP reporter
viruses. In the absence of MVC, total CD4+ T-cell infection was
comparable for all MVC sensitive and MVC resistant Envs (Fig. 2).
Similar results were obtained with JR-CSF Env (Supplementary
Fig. 1A). The addition of MVC ostensibly abolished the infectivity of
the MVC sensitive Envs (Fig. 2A) and JR-CSF Env (Supplementary
Fig. 1A) in CD4+ T-cells, but had variable effects on the infectivity
of the MVC resistant Envs (Fig. 2B). MVC had no affect on the
“strongly resistant” 24-Res Env, but caused incomplete reductions
of infectivity of the “moderately resistant” and “weakly resistant”
Envs (MVC-Res and 17-Res Envs, respectively) (Fig. 2B).
In the presence of drug, the MVC resistant Envs used here are
forced to recognize the drug-bound conformation of CCR5 by
adopting an increased reliance on the CCR5 N-terminus and an
altered recognition of the CCR5 ECLs (Roche et al., 2011b, 2013).The different MPIs for the 3 resistant Envs suggests that they
recognize MVC-bound CCR5 with different efﬁciencies (Table 2).
To determine whether this has an effect on the susceptibility of
alternative CD4+ T-cell subsets to HIV-1 infection, we next
determined the composition of the HIV-1 infected T-cell popula-
tion when MVC was either present or absent (Fig. 3). In uninfected
cells, we ﬁrst veriﬁed that MVC on its own had no affect on the
overall proportion of T-cell subsets (data not shown). We also
showed that the level of CD4 expression was similar across the
T-cell subsets (data not shown). However, CCR5 expression varied
with the highest expression on EM and TM cells (18713% and 15
78%, respectively), a relatively moderate expression on CM cells
(9 76%) and very low expression on EMRA and naïve cells (both
171%). The distribution of CD4 and CCR5 expression across the
T-cell subsets is similar to that reported previously for peripheral
blood CD4+ T-cell subsets (Bleul et al., 1997; Gorry and Ancuta,
2011; Lee et al., 1999a, 1999b; Pfaff et al., 2010). The distribution of
infection in EM, TM and CM cells by virus pseudotyped with the
control JR-CSF Env is shown in Supplementary Fig. 1B. In the
presence of MVC, the “strongly resistant” 24-Res Env displayed a
signiﬁcant shift in the distribution of infected T-cells, characterized
by an increase in CM T-cell infection and decreases in TM and EM
T-cell infection (Fig. 3). In contrast, the “moderately resistant” and
“weakly resistant” MVC-Res and 17-Res Envs showed no change in
the distribution of infected T-cells by the presence of MVC (Fig. 3).
None of the MVC resistant Envs showed changes in the distribu-
tion of HIV-1 infection in naïve T-cells and EMRA T-cells by the
presence of MVC (data not shown). These results suggest that the
Fig. 2. CD4+ T-cell infectivity by MVC sensitive and resistant Envs. CD4+ T-cells
were infected with GFP reporter viruses pseudotyped with MVC-sensitive (A) or
MVC-resistant Envs (B), in the presence or absence of 10 μM MVC as described in
Materials and methods. Infection of CD4+ T-cells was measured by the percentage
of cells positive for both CD3 and GFP expression, as shown in Fig. 1A. The data
shown are a compilation of experiments performed in 5 independent PBMC
donors, with the exception of infections with 17-Sens and 24-Sens Envs in the
presence of MVC, which was conducted in cells from 2 donor. The bar graphs
represent means and standard deviations. Statistical analysis was conducted using
a Wilcoxon signed rank test.
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have an inﬂuence on whether the virus can exhibit tropism
alterations for CD4+ T-cell subsets.
Our results are in contrast to those of a recent study of HIV-1
resistance to APL, which showed a signiﬁcant increase in the
number of EM T-cells infected and a relative sparing of CM-T-cells
from infection (Pfaff et al., 2010). The conformational changes
induced by different CCR5 antagonists, however, are not identical
as the ability to displace the binding of conformation-dependant
CCR5 mAbs varies between antagonists (Tilton et al., 2010). This
suggests that different CCR5 antagonists could work in slightly
different ways, with an altered interaction of HIV-1 with different
T-cell subsets possibly being promoted by differences in the
structure of the alternative drug-bound CCR5 conformations.
Interestingly, consistent with previous studies (Gorry and Ancuta,
2011), the CM T-cells had lower CCR5 expression levels than the EM
and TM T-cells, and the “strongly resistant” 24-Res Env demonstrated
an enhanced ability to infect CM T-cells in the presence of MVC.
Together with the 293-afﬁnoﬁle studies and VERSA metrics where
24-Res did not show a substantial increase in CCR5 dependence
compared to the other resistant strains in the presence of MVC
(Table 2), these results suggest the efﬁciency of 24-Res Env to
recognize MVC-bound CCR5 is relatively high. This may permit
infection of CM T-cells that have relatively low CCR5 expression
levels. Curiously, 24-Res Env exhibited relative sparing of EM and TM
T-cells, despite these cells expressing higher levels of CCR5 than CM
T-cells. The reasons for this are unclear, but may be related to
different afﬁnities for CCR5 with alternative conformations and/orpost-translational modiﬁcations that may exist on different T-cell
subsets (Doms, 2000; Doms and Trono, 2000), and/or differences in
CCR5 conformations on the T-cell subsets that may be differentially
recognized by Envs with resistance to different CCR5 antagonists
(Berro et al., 2011). Alternatively, preferential infection of CM T-cells
may have resulted in relative sparing of EM and TM T-cells by
depleting the number of infectious viruses available for infection of
these cells.
Macaque studies of simian immunodeﬁciency virus (SIV) infec-
tion showed that prolonged survival was associated with preser-
vation of the CM T-cell subset, whereas the loss of these cells
correlated with a loss of EM T-cells and progression to AIDS
(Okoye et al., 2007). Further studies of HIV-1 infected individuals
showed that both CM and TM T-cells are distinct reservoirs of HIV-
1, where infection of CM T-cells is regulated by antigen-driven
proliferation and infection of TM T-cells by homeostatic prolifera-
tion (Chomont et al., 2009). CM T-cells in particular are a
persistent HIV-1 reservoir as they can survive for years (Riou
et al., 2007; Sallusto et al., 1999). These data suggest that enhanced
infection of CM T-cells by 24-Res Env could be detrimental. If this
proves to be a frequent property in wider cohorts of patients with
MVC resistance, it would caution against the idea of continuing
MVC therapy after resistance has developed to promote virus
attenuation (Pfaff et al., 2010; Roche et al., 2011b)
We acknowledge that the results of our study need to be
conﬁrmed in larger patient cohorts with larger numbers of Env
clones in order to evaluate the potential clinical signiﬁcance of our
ﬁndings. A larger sample size with a spread of timepoints would
also assist in characterizing markers for tropism changes during
the development of MVC resistance. Although the proportions of
CD4+ T cell subsets were representative of those found in vivo, we
recognize limitations of the multiparametric ﬂow-based system
for quantifying HIV-1 infection in CD4+ T-cell subsets, including
the use of single-cycle infections which may not completely reﬂect
the properties of replicating virus in vivo.
MVC resistant Envs have different patterns of altered macrophage
tropism
Our previous studies showed that the infectivity of the “moderately
resistant” MVC-Res Env is abolished in MDM due to a relatively
inefﬁcient ability of this Env to recognize the MVC-bound conforma-
tion of CCR5 on macrophages (Roche et al., 2011b). We hypothesized
that this might not necessarily be the case for MVC resistant Envs that
have a more efﬁcient interaction with MVC-bound CCR5, such as
24-Res Env (Roche et al., 2013). We therefore next characterized
macrophage infectivity of the “strongly resistant” 24-Res Env and the
“weakly resistant” 17-Res Env compared to their MVC sensitive
parental Envs, in the presence or absence of MVC (Fig. 4). For these
experiments we used Env-pseudotyped luciferase reporter viruses and
two R5 control Envs that have well characterized infectivity proﬁles in
MDM; YU-2 is a highly M-tropic R5 Env, and JR-CSF is a comparatively
poorly M-tropic R5 Env (Salimi et al., 2013). In the absence of MVC, all
the Envs from subjects 17 and 24 were comparatively poorly M-tropic,
with infectivities comparable to- or lower than that of JR-CSF (Fig. 4A).
Nonetheless, both the resistant Envs showed signiﬁcantly increased
entry into MDM than their respective parental sensitive Envs when
they were able to interact with drug-free CCR5. However, in the
presence of MVC when the resistant Envs are forced to recognize
MVC-bound CCR5, the infectivity of the “weakly resistant” 17-Res Env
was almost completely abolished (Fig. 4B), similar to proﬁle seen with
the “moderately resistant” MVC-Res Env (Roche et al., 2011b). In
contrast, MVC had no affect on the infectivity of the “strongly
resistant” 24-Res Env in MDM (Fig. 4B). Together, these results show
that the “strongly resistant” 24-Res Env can utilize the drug-bound
and drug-free CCR5 conformations to an equivalent degree on MDM,
Fig. 3. The effect of MVC on HIV-1 tropism for CD4+ T-cell subsets by MVC resistant Envs. CD4+ T-cells were infected with Env-pseudotyped GFP reporter viruses in the
presence or absence of 10 μM MVC as described in Materials and methods, and the percentage of infected CD4+ T-cells that were identiﬁed as EM, TM or CM T-cells was
determined as shown in Fig. 1. The data shown are from 5 independent experiments performed in cells obtained from different donors. Each data point represents mean
values of triplicates. Statistical analysis was conducted using a Wilcoxon signed rank test.
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CCR5 on MDM.Conclusions
Together, these data suggest that Envs with “strong resistance” to
MVC are still able to infect CD4+ T-cells and macrophages to a similar
level, regardless of whether the Env uses the drug-free or drug-bound
CCR5 conformation. The data highlights the ability of these Envs to
alter tropism for CD4+ T-cell subsets, with an enhanced infection of
CM T-cells. If this occurs more broadly in subjects withMVC resistance,
it may contribute to increasing the HIV-1 reservoir size with poten-
tially detrimental consequences for disease progression. In contrast,
Envs with “weak” or “moderate” MVC resistance may not display
tropism alterations for CD4+ T-cell subsets, but could have attenuated
M-tropism in the presence of MVC. The pattern of tropism alterations
for different susceptible cell types exhibited by MVC resistant Envs
appears to be associated with the level of resistance. However, further
studies of additional in vivo-generated MVC-resistant strains from
additional MVC-treated subjects are required to conﬁrm this associa-
tion and its potential clinical relevance.Materials and methods
Cells
293 T cells, JC53 cells (Platt et al., 1998), TZM-bl cells (Wei et al.,
2002) and NP2-CD4/CCR5 cells (Shimizu et al., 2009) were cultured in
DMEM supplemented with 10% (vol/vol) fetal calf serum (FCS), and100 μg of penicillin and streptomycin per ml. Peripheral blood mono-
nuclear cells (PBMC) were puriﬁed from the blood of healthy HIV-1
negative donors by density gradient centrifugation. Monocytes were
puriﬁed from PBMC by plastic adherence and allowed to differentiate
into monocyte-derived macrophages (MDM) by culturing for 5 days in
IMEM supplemented with 10% (vol/vol) pooled AB+ human sera,
100 μg of penicillin and streptomycin per ml, and 12.5 ng of macro-
phage colony-stimulating factor per ml.
Env plasmids
This study characterized Env clones from two subjects (referred to
as subjects 17 and 24) who commencedMVC as part of the MOTIVATE
phase III clinical trial and developed phenotypically veriﬁed MVC
resistance, as well as parental Env clones from the same subjects prior
to commencing MVC (Jubb et al., 2011; Mori et al., 2008; Pﬁzer Inc.,
2007). These clones are referred to as 17-Sens, 17-Res, 24-Sens and 24-
Res, and their phenotypes and genotypes associated with MVC
resistance have been described in detail recently (Roche et al., 2013).
Of note, all are of R5 phenotype. MVC-Res is an R5 Env derived from
the CC1/85 HIV-1 strain that was passaged in PBMC in the presence of
increasing concentrations of MVC to generate MVC resistance in vitro
(Roche et al., 2011a, 2011b; Westby et al., 2007). MVC-Sens is the
parental Env from CC1/85. YU-2 and JR-CSF are R5 Envs that were
used as controls. All Envs were cloned into the pSVIII-Env expression
vector (Gao et al., 1996).
Production and quantitation of Env-pseudotyped GFP reporter viruses
Env-pseudotyped, GFP reporter viruses were produced by transfec-
tion of 293 T cells with pNL4-3Env-GFP (Center et al., 2009) and
Fig. 4. The effect of MVC on HIV-1 tropism for macrophages by MVC sensitive and
resistant Envs. (A) Monocyte-derived macrophages were infected with Env-pseu-
dotyped luciferase reporter viruses, as described in Materials and methods, and
entry levels were expressed as a percentage of that attained by virus pseudotyped
with YU-2 Env. In these experiments the luciferase activity in MDM infected with
virus pseudotyped with YU-2 Env was approximately 1106 relative light units
(RLU) compared to approximately 5103 RLU in negative control wells.
(B) Luciferase reporter viruses pseudotyped with 17-Res and 24-Res Envs were
used to infect MDM in the presence or absence of 10 μM MVC. The level of virus
entry in the presence of MVC was expressed as a percentage of entry attained by
the same Env in the absence of MVC. Results are a compilation of 5 independent
experiments performed in cells obtained from 5 different donors. Bar graphs
represent the means and SEM.
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of 4:1. Supernatants were harvested 48 h later and ﬁltered through
0.45 mm ﬁlters. Viruses were concentrated through a 20% (vol/vol)
sucrose cushion, and stored at −80 1C. The TCID50 of virus stocks was
determined by titration in TZM-bl cells, as described previously (Wei
et al., 2002; Yap et al., 2007).
Enumeration of HIV-1 infection in CD4+ T-cell subsets
We developed a system for quantifying HIV-1 infection in CD4+
T-cell subsets that was based on a previously published protocol
(Pfaff et al., 2010). 48-well plates were coated with 5 ug/mL anti-
CD3 (Beckman Coulter) and 5 ug/mL anti-CD28 (BD Biosciences)
for 12 h at 4 1C. Plates were washed and seeded with 4106/mL
CD4+ T cells that were isolated from healthy donors using aRosetteSep CD4+ T-cell kit (Stemcell Technologies). Cells were
suspended in RPMI 1640 medium containing 10% (vol/vol) FCS and
20 U/ml IL-2 (Sigma-Aldrich) at all stages of the experiment. CD4+
T-cells were incubated for 3 days prior to infection with 3000
infectious units of Env-pseudotyped GFP reporter virus by spino-
culation (1200 g for 2 h) in V-bottom 96-well plates. We empiri-
cally determined that this virus inoculum was within the linear
range of infection (data not shown). Virus infection was performed
in the presence or absence of 10 mM MVC. Cells were then
transferred to 48-well plates for 3 days prior to staining with ﬂow
cytometry antibodies for CD3-APCCy7 (BD Biosciences), CCR5-PE
(BD Biosciences), CCR7-AF647 (BD Biosciences), CD45RO-
eFluor450 (eBiosciences), CD27-PeCy7 (BD Biosciences) and a
ﬁxable viability dye (eFlour506, eBiosciences). HIV-1 infection
was determined by CD3/GFP positivity and used to determine
the distribution of infection amongst CD4+ T-cell subsets, which
were deﬁned as; naïve (CCR7+CD45RO−), effector memory RA
(EMRA, CCR7−CD45RO−), central memory (CM, CCR7+CD45RO+),
effector memory (EM, CCR7−CD45RO+CD27−) and transitional
memory (TM, CCR7−CD45RO+CD27+) T-cells. For these analyses,
one million events were collected on a LSRFortessa ﬂow cytometer
(BD Biosciences) and analyzed with Gatelogic software (Inivai).
The strategy for measuring HIV-1 infection in CD4+ T-cell subsets
is shown in Fig. 1, which is a representative experiment using GFP
reporter virus pseudotyped with MVC-Res Env in the absence
of MVC.
Production and quantitation of Env-pseudotyped luciferase reporter
viruses
Env-pseudotyped, luciferase reporter viruses were produced by
transfection of 293 T cells with pCMVΔP1ΔenvpA, pHIV-1Luc and
pSVIII-Env plasmids using Lipofectamine 2000 (Invitrogen) at a
ratio of 1:3:1, as described previously (Gray et al., 2006; Sterjovski
et al., 2007; Yang et al., 2001). Supernatants were harvested 48 h
later, ﬁltered through 0.45 mm ﬁlters and stored at −80 1C. The
TCID50 of virus stocks was determined by titration in JC53 cells
(Platt et al., 1998), as described previously (Gray et al., 2009; Roche
et al., 2011a, 2011b)
HIV-1 entry assays in monocyte-derived macrophages
For single-round entry assays using MDM, cell monolayers that
were approximately 90% conﬂuent in 48-well tissue culture plates
were inoculated with 500 TCID50 of Env-pseudotyped luciferase
reporter virus in a volume of 300 μl for 12 h at 37 1C, in the
presence or absence of 10 μM MVC. The MDM were then washed
twice with culture medium to remove residual inoculum and
incubated for a further 96 h at 37 1C. The level of HIV-1 entry was
measured by luciferase activity in cell lysates (Promega), according
to the manufacturers' protocol. Luminescence was measured using
a FLUOStar Optima microplate reader (BMG LABTECH, GmbH,
Germany). Negative controls included mock-infected cells that
were incubated with culture medium instead of virus, and cells
inoculated with luciferase reporter virus pseudotyped with the
non-functional ΔKS Env (Etemad-Moghadam et al., 2000).Acknowledgments
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